1 February 2010
We are pleased to announce the availability of a new report that may be of interest to some readers; Predicting the risk of coronary heart disease with conventional, genetic and novel molecular biomarkers considers issues of how best to assess risk and use emerging genetic and molecular biomarkers, and forms part of wider work at the PHG Foundation looking at quality standards in disease risk prediction. Interestingly, although a new genome-wide association study has provided valuable insight into the underlying biology of type 2 diabetes, another study has shown that genetic risk factors do not improve current risk prediction models for the condition (19 January).
Pre-conceptual genetic testing and prenatal genetic diagnosis have been in the UK news this month; first with some rather questionable coverage on the use of PGD for less serious conditions (26 January) and more recently with the news that a preconceptual genetic test for over one hundred conditions is to be launched here (9 February). In the US, a recommendation has been made that forms of severe combined immunodeficiency (SCID) should join the standard panel of conditions for newborn screening (8 February), whilst in Australia new guidance on genetics and patient confidentiality has been released (25 January).
A report by the UK Academy of Medical Sciences calls for the Government to capitalise on the opportunities for medical research with a proportionate regulatory environment and improved coordination of research in different sectors (22 January). A new open access database is offering chemogenomic data to drive pharmaceutical research (7 February), and a new synthetic biology facility has launched with plans to develop and make freely available standardised DNA parts (14 February). A major new international consortium has been established to further understanding of genetic and environmental contributions to health and disease (5 February), whilst in the US a new projects seeks to determine the genetic origins of a range of paediatric cancers (1 February).
In the literature this month, papers suggests that genetic information from prostate biopsies could be useful for prognosis (12 February); that epigenetic changes may be linked to heart failure (15 January); and that a genetic variant is linked with decreased risk of dementia (18 January). The proposal that rare genetic variants may play a major role in common diseases and particularly, that many associations with common genetic variants may be false, has generated some controversy (1 February). A new method for expanding numbers of cord blood stem cells shows promise for treatment of leukaemias and other diseases of the blood (22 January), whilst another paper reports on the use of rapid DNA sequencing to monitor the spread of MRSA strains (28 January).
Our selection of recent articles of interest (3 February)